Director of Research, Global Industries, Bloomberg Intelligence. Views my own. Not recommending buy/hold/sell.

Joined October 2019
205 Photos and videos
Leerink is on a role and it’s a great positive sign for the sector too: a big M&A $NUVL and a very successful IPO $PBLS - congrats.
1
8
1,399
Wish I could spell :-) on a roll!!
3
413
With ASCO behind us, it was time to catch up with Susan Galbraith at $AZN. Another excellent conversation on oncology with one of the leaders in the area. podcasts.apple.com/gb/podcas…
1
3
14
1,535
$ELV $GDRX $HIMS $LLY $UNH $BBMX $MMED $PODD $TNDM $ABT $DXCM $BMRN $ASND $CRBP $GMAB $MRK $PFE $BCAB $JNJ DC Update, Diabetes Devices, Voxzogo, ASCO Data: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/PXHaftEY2F…

2
880
Some people will get heart palpitations about this deal on the eve of #ASCO2026 blinks.bloomberg.com/news/st…

1
3
1,817
It includes co-comercialization globally - a rare thing. How does a Chinese company commercialise the same drug in the US and China in the world of MFN?
2
7
1,173
$CELC $RHHBY $BMY $NVS $AZN $JNJ $GILD $GSK $INCY $CGON $CADL $TARA Myeloma Survey; Oncology VC Funding; ASCO Previews: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/6cznBtPmxN…

1
6
831
Sam Fazeli retweeted
Managing Partner and Chief Investment Officer @docrodwong recently joined @SamFazeli8 on @BBGIntelligence's Vanguards of Health Care podcast to discuss biotech's comeback, China and AI's impact on drug discovery, and why all eyes are on #ASCO2026 this year. Listen to the full episode here: bloomberg.com/news/audio/202…
1
1
697
$INBX $MRK $RHHBY $AZN $LLY $OLMA $BING $ZLDPF $NVO $PFE Hear InhibRx Data, $15B SERDs Market, Obesity at ADA: BI Drug Call, a playlist on #SoundCloud on.soundcloud.com/VftUfzdIbB…

4
6,005
Sam Fazeli retweeted
On today’s #BiotechHangout @SamFazeli8, @biotech1 (Josh Schimmer), @EricSchmidt151, & @t_lorriman will cover deals & financings: $BMY/Hengrui up to ~$15B partnership deal, $ARVN/ $PFE $85M upfront licensing deal w/$RIGL for newly approved Veppanu, Isomorphic’s massive $2.1B Series B, policy & regulatory: Makary’s resignation & what this means for biotech, plus company news & data: $BIIB tau data, $INBX interim Phase 2 data & major stock shifts, $MRNA Hantavirus vaccine, & what’s hot at #ASCO2026, #ADA2026, & #EHA2026 & much more: twitter.com/i/spaces/1nJOLEZ…
14
3
9
3,885
$LLY $NVO $ASND $PFE $MRK $RHHBY $ZLDPF $RVMD $ERAS $NVS Obesity Latest, KRAS & Growth Hormone Updates: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/J1vsQUJVlT…

9
2,427
This is very promising, allowing drugs to get to patients faster and costing pharma companies a little less. But getting to market faster only increases the NPV of the drug by as much as IRA would allow. Now what the industry and FDA need to do is to speed up the process of getting drugs into man faster to catch up with China.
Real-time clinical trials could fundamentally transform the clinical trial landscape.
1
1
18
3,555
$LLY $NVO $ RHHBY $RVMD $AZN $JAZZ $ZYME $AMGN $BMY $TNGX $VSTM $ABBV $MRK $PFE $ZLAB $SMMT Obesity Medicare Coverage, AACR Highlights: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/8hSiUGwm8x…

5
1,764
Again a bit late - @AACR got in the way. $REGN $RVMD $BMY $ALLO $GSK $INCY $ABBV $MRK $GMAB $RHHBY Regeneron vs. Bristol; RevMed, ALLO, GSK Data: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/YNSsw6Xg2b…

8
1,889
$NVO $GILD $VTRS $ABBV $MRK $CORT $GMAB $LLY $GSK $BNTX $PFE $RHHBY Gilead M&A, New Tariffs, Wegovy Patent, SGO Data: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/TfyCye6bfd…

2
11
2,397
A bit late - Easter threw me. Policy Risk, Biogen M&A, Vyndamax Suits, ECLC Data: BI Drug Call by Bloomberg Intelligence on #SoundCloud on.soundcloud.com/wgAUKna1er…

4
735
$ISLMF Given the deal with $LLY, I was very lucky to have planned this podcast with Alex Zhavoronkov, CEO of Insilico. All about AI and drug discovery. podcasts.apple.com/gb/podcas…
1
8
565